Breast enhanced scintigraphy testing distinguishes between normal, inflammatory breast changes, and breast cancer: A prospective analysis and comparison with mammography

Integrative Cancer Therapies

Volumn 1, Issue 3, 2002, Pages 238-245

  Fleming, Richard M ^b   Dooley, William C ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b Camelot Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPYRIDAMOLE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOISOTOPE;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST DISEASE; BREAST TUMOR; CANCER SCINTISCANNING; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DRUG MEGADOSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTITIS; METHODOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOGRAPHY; REFERENCE VALUE; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VASODILATATION;

EID: 0042823898     PISSN: 15347354     EISSN: None     Source Type: Journal    
DOI: 10.1177/153473540200100303     Document Type: Article

References (29)

1. American Heart Association. Heart and Stroke Statistical Update. American Heart Association; 1998.
2. The Health Network. Retrieved November 16, 1999, from http://www.thehealthnetwork.com
3. Burman ML, Taplin SH, Herta DF, Elmore JG. Effect of false-positive mammograms on interval breast cancer screening in a health maintenance organization. Ann Intern Med. 1999;131:1-6.
4. Fletcher SW. False-positive screening mammograms: good news, but more to do. Ann Intern Med. 1999;131:60-61.
5. Christiansen CL, Wang F, Barton MB, et al. Predicting the cumulative risk of false-positive mammograms. J Natl Cancer Inst. 200;92:1657-1666.
6. Rissanen TJ, Makarainen HP, Mattila SI, Lindholm EL, Heikkinen MI, Kiviniemi HO. Breast cancer recurrence after mastectomy: diagnosis with mammography and US. Radiology. 1993;188:463-467.
7. Eary JF. Nuclear medicine in cancer diagnosis. Lancet. 1999;354:853-857.
8. He J, Li Y, Su J. Differentiation of benign and malignant palpable breast masses using 99m Tc-MIBI imaging. Hunan I Ko Ta Hsueh Hsueh Pao. 1997;22:226-228.
9. Palmedo H, Biersack HJ, Lastoria S, et al. Scintimammography with technetium-99m methoxyisobutylisonitrile: results of a prospective European multicentre trial. Eur J Nucl Med. 1998;25:375-385.
10. Tilling R, Tatsch K, Sommer H, et al. Technetium-99m-sestamibi scintimammography for the detection of breast carcinoma: comparison between planar and SPECT imaging. J Nucl Med. 1998;39:849-856.
11. Salvatore M, Del Vecchio S. Dynamic imaging: scintimammography. Eur J Radiol. 1998;27:S259-S264.
12. Buscombe JR, Cwikla JB, Thakrar DS, Hilson AJ. Scintigraphic imaging of breast cancer: a review. Nucl Med Commun. 1997;18:698-709.
13. Cwikla JB, Buscombe JR, Barlow RV, et al. The effect of chemotherapy on the uptake of technetium-99m sestamibi in breast cancer. Eur J Nucl Med. 1997;24:1175-1178.
14. Cwikla JB, Buscombe JR, Kelleher SM, et al. Comparison of accuracy of scintimammography and X-ray mammography in the diagnosis of primary breast cancer in patients selected for surgical biopsy. Clin Radiol. 1998;53:274-280.
15. Amano S, Inoue T, Tomiyoshi K, Ando T, Endo K. In vivo comparison of PET and SPECT radiopharmaceuticals in detecting breast cancer. J Nucl Med. 1998;39:1424-1427.
16. Bombardieri E, Crippa F, Maffioli L, et al. Nuclear medicine approaches for detection of axillary lymph node metastasis. QJ Nucl Med. 1998;42(1):54-65.
17. Gulec SA, Moffat FL, Carroll RG, Krag DN. Gamma probe guided sentinel node biopsy in breast cancer. QJ Nucl Med. 1997;41:251-261.
18. Taillefer R, Robidoux A, Turpin S, Lambert R, Cantin J, Leveille J. Metastatic axillary lymph node technetium-99m-MIBI imaging in primary breast cancer. J Nucl Med. 1998;39:459-464.
19. Fleming RM, Dooley WC, Boyd LB, Kubovy K. Breast enhanced scintigraphy testing (BEST) - increased accuracy in detecting breast cancer accomplished by combining breast and cardiac imaging. Paper presented at: 48th Annual Scientific Session of the Society of Nuclear Medicine; June 27, 2001; Toronto, Ontario, Canada.
20. Fleming RM, Boyd L, Forster M. Angina is caused by regional blood flow differences - proof of a physiologic (not anatomic) narrowing. Paper presented at: Joint Session of the European Society-American College of Cardiology, ACC 49th Annual Scientific Sessions; March 12, 2000; Anaheim, CA.
21. Fleming RM. Regional blood flow differences induced by high dose dipyridamole explain etiology of angina. Paper presented at: 3rd International College of Coronary Artery Disease From Prevention to Intervention; October 4, 2000; Lyon, France.
22. Fleming RM. Nuclear cardiology: its role in the detection and management of coronary artery disease. In: Chang JC, ed. Textbook of Angiology. NewYork, NY: Springer-Verlag; 1999:397-406.
23. Dooley WC. Endoscopic visualization of breast tumors. JAMA. 2000;284:1518.
24. Screening for breast cancer. Harvard Medical School Consumer Health Information. Retrieved February 27, 2001, from http://www.intelihealth.com.
25. Fleming RM, Boyd LB, Kubovy C. Myocardial perfusion imaging using high dose dipyridamole defines angina: the difference between coronary artery disease (CAD) and coronary lumen disease (CLD). Paper presented at: 48th Annual Scientific Session of the Society of Nuclear Medicine; June 27, 2001; Toronto, Ontario, Canada.
26. Fleming RM, Dooley WC, Boyd LB, Kubovy C. Breast enhanced scintigraphy testing (BEST) - increased accuracy in detecting breast cancer accomplished by combining breast and cardiac imaging. Paper presented at: 48th Annual Scientific Session of the Society of Nuclear Medicine; June 26, 2001; Toronto, Ontario, Canada.
27. Fleming RM. The pathogenesis of vascular disease. In: Chang JC, ed. Textbook of Angiology. New York, NY: Springer-Verlag; 1999:787-798.
28. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med. 1971;133:275-288.
29. Stewart RJ, Panigraphy D, Flynn E, Folkman J. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol. 2001;165:688-693.